Abstract
The use of botulinum neurotoxins (BoNTs) for therapeutic purposes in neuromuscular disorders and peripheral hypercholinergic conditions as well as in aesthetic medicine is widespread and common. BoNTs are also able to block the release of a wide range of transmitters from presynaptic boutons. Therefore, application of BoNTs directly in the central nervous system (CNS) is currently under study with respect to basic research and potentially as a new therapeutic strategy of neurological diseases. Investigations concentrate on effects of intracerebral and intraspinal application of BoNTs in rodents on the impact on spinal, nuclear, limbic and cortical neuronal circuits. In animal model first promising BoNTinduced therapeutical benefit has been shown in the treatment of pain, epilepsy, stroke and Parkinson’s disease.
Keywords: Botulinum neurotoxin, dementia, epilepsy, hippocampus, ischemia, Parkinson’s disease, spinal cord, striatum
Current Pharmaceutical Biotechnology
Title:Intracerebrally Applied Botulinum Neurotoxin in Experimental Neuroscience
Volume: 14 Issue: 1
Author(s): Alexander Hawlitschka, Veronica Antipova, Oliver Schmitt, Martin Witt, Reiner Benecke, Eilhard Mix and Andreas Wree
Affiliation:
Keywords: Botulinum neurotoxin, dementia, epilepsy, hippocampus, ischemia, Parkinson’s disease, spinal cord, striatum
Abstract: The use of botulinum neurotoxins (BoNTs) for therapeutic purposes in neuromuscular disorders and peripheral hypercholinergic conditions as well as in aesthetic medicine is widespread and common. BoNTs are also able to block the release of a wide range of transmitters from presynaptic boutons. Therefore, application of BoNTs directly in the central nervous system (CNS) is currently under study with respect to basic research and potentially as a new therapeutic strategy of neurological diseases. Investigations concentrate on effects of intracerebral and intraspinal application of BoNTs in rodents on the impact on spinal, nuclear, limbic and cortical neuronal circuits. In animal model first promising BoNTinduced therapeutical benefit has been shown in the treatment of pain, epilepsy, stroke and Parkinson’s disease.
Export Options
About this article
Cite this article as:
Hawlitschka Alexander, Antipova Veronica, Schmitt Oliver, Witt Martin, Benecke Reiner, Mix Eilhard and Wree Andreas, Intracerebrally Applied Botulinum Neurotoxin in Experimental Neuroscience, Current Pharmaceutical Biotechnology 2013; 14 (1) . https://dx.doi.org/10.2174/1389201011314010015
DOI https://dx.doi.org/10.2174/1389201011314010015 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Histone Acetylation as a Potential Therapeutic Target in Motor Neuron Degenerative Diseases
Current Pharmaceutical Design Preparation of Tiagabine HCl/2-HPβCD Complex Pellets by Extrusion-Spheronization Using Glycerol Monostearate as Pellet-Aid
Letters in Drug Design & Discovery Tryptamine Induces Axonopathy and Mitochondriopathy Mimicking Neurodegenerative Diseases via Tryptophanyl-tRNA Deficiency
Current Alzheimer Research Neurological Disorders in Medical Use of <i>Cannabis</i>: An Update
CNS & Neurological Disorders - Drug Targets Action Mechanisms of Chinese Herbal Compound at the Molecular Level
Letters in Drug Design & Discovery Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders
Current Pharmaceutical Design A Review on GABA/Glutamate Pathway for Therapeutic Intervention of ASD and ADHD
Current Medicinal Chemistry Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences
Current Neuropharmacology 3D-QSAR Study of Some Heterocyclic Sulfonamide Analogs as hCAII Inhibitors
Letters in Drug Design & Discovery Recent Developments of the PET Imaging Agents for Metabotropic Glutamate Receptor Subtype 5
Current Topics in Medicinal Chemistry CT-negative Subarachnoid Hemorrhage Caused by Telangiectasia: A Case Report
Current Medical Imaging The New Challenges of Brain PET Imaging Technology
Current Medical Imaging The Biology of the RNA Binding Protein Guanine-Rich Sequence Binding Factor 1
Current Protein & Peptide Science Early Age of Migraine Onset is Independently Related to Cognitive Decline and Symptoms of Depression Affect Quality of Life
Current Neurovascular Research Role of Natural Plant Products Against Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Repetitive Transcranial Magnetic Stimulation (rTMS) to Treat Refractory Panic Disorder Patient: A Case Report
CNS & Neurological Disorders - Drug Targets Novel Treatment Options of Binge Eating Disorder
Current Medicinal Chemistry The Clinical Difference between Gabapentin and Pregabalin: Data from a Pilot Comparative Trial
Reviews on Recent Clinical Trials Fetal Programming of the Human Brain: Is there a Link with Insurgence of Neurodegenerative Disorders in Adulthood?
Current Medicinal Chemistry The Effects of Soluble Aβ Oligomers on Neurodegeneration in Alzheimer's Disease
Current Pharmaceutical Design